StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

Duloxetine Hydrochloride

HCID 60834
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
136434-34-9
Standard-SMILES
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl
InChIKey
BFFSMCNJSOPUAY-LMOVPXPDSA-N
Summenformel
C18H20ClNOS
Durchschnittliche Molmasse
333,9 g/mol
Monoisotopische Masse
333,09541294

Überblick

(S)-duloxetine hydrochloride is a duloxetine hydrochloride in which the duloxetine moiety has S configuration. It has a role as an antidepressant. It contains a (S)-duloxetine.

Namen und Bezeichner

Bevorzugter Name
Duloxetine Hydrochloride
IUPAC
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
Englischer Name
Duloxetine hydrochloride
Summenformel
C18H20ClNOS
Molmasse
333.88

Namen und Synonyme

DULOXETINE HYDROCHLORIDE136434-34-9Duloxetine HClAriclaimDuloxetine mylanDTXSID9046443LY248686 HClLY-248686 HClDuloxetine (as hydrochloride)NSC-7591129044SC542WDuloxetine Boehringer Ingelheim
Weitere Namen anzeigen
DuloxetimeDuL(S)-DULOXETINE HYDROCHLORIDECS-488LY-248686CAS:136434-34-9S-Duloxetine HCloxetine HydrochL
DTXCID7026443CHEBI:31526DRIZALMA SPRINKLECHEBI:36808DuloxicaineDuciltiaDuloxetine DRHCl, Duloxetine

Datenbank-Bezeichner

CAS
136434-34-9
PubChem CID
60834
DTXSID
DTXSID9046443
ChEMBL
CHEMBL1200328
ChEBI
CHEBI:31526

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

Polarare Oberfläche (TPSA)
49,5 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
6
Schwere Atome
22
Formalladung
0
Komplexität
312

Experimentelle und physikochemische Eigenschaften

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin-Norepinephrine Reuptake Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Collision Cross Section168.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
118 · 118-122°C
Flammpunkt
9 ℃ · 9℃
storage temp.
room temp
Löslichkeit
2 O: · H2O: soluble5mg/mL (clear solution, warmed)
pka
pKa in DMF-water (66:34): 9.6(at 25℃)
Aggregatzustand
powder
Farbe
white to beige
Merck
14 · 14,3465
Major Application
pharmaceutical (small molecule)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (15.2%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P301+P317, P305+P354+P338, P317, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 66 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 3 (15.2%)

Toxikologische Informationen

Treatment · 1 Eintrag

There is no specific antidote to Duloxetine, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting absorption of duloxetine from the gastrointestinal tract. Administration of activated charcoal has been shown to decrease AUC and Cmax by an average of one-third, although some subjects had a limited effect of activated charcoal. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial. (L1712)

Exposure RoutesOrally administered duloxetine hydrochloride is well absorbed.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine. Route of Elimination: Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces. Half Life: 12 hours (range 8-17 hours)

FDA Pharmacological Classification · 6 Einträge

DULOXETINE HCL

Norepinephrine Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

DULOXETINE HYDROCHLORIDE

Serotonin Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Norepinephrine Uptake Inhibitors [MoA]

DULOXETINE D/R

Serotonin Uptake Inhibitors [MoA]; Norepinephrine Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]

MeSH Pharmacological Classification · 4 Einträge

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Zugehörige Reaktionen

18
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 222780
HRID 222780als Produktuspto-grants-2012_06
Reaktionsgleichung von HRID 222785
HRID 222785als Produktuspto-grants-2012_06
Reaktionsgleichung von HRID 420011
HRID 420011als Produktuspto-grants-2012_01
Reaktionsgleichung von HRID 656685
HRID 656685als Produktuspto-grants-2011_12
Reaktionsgleichung von HRID 656690
HRID 656690als Produktuspto-grants-2011_12
Reaktionsgleichung von HRID 1176066
HRID 1176066als Produktuspto-grants-2010_11
Reaktionsgleichung von HRID 1694626
HRID 1694626als Produktuspto-grants-2012_04
Reaktionsgleichung von HRID 1715781
HRID 1715781als Produktuspto-grants-2010_09
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
UNII
9044SC542W
EC Number
603-962-5
InChI
InChI=1/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/s3
InChIKey
BFFSMCNJSOPUAY-VOPAOICTNA-N
SMILES
C1(=CC=CS1)[C@H](CCNC)OC1=CC=CC2=CC=CC=C12.Cl |&1:5,r|
Toxicity Summary · 1 Eintrag

Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

Signs and SymptomsSymptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Duloxetine hydrochloride

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataOral, rat LD<sub>50</sub>: 491 mg/kg for males and 279 mg/kg for females (A308).

Sicherheitsdaten

wgk
3
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29349990
RTECS-Nr.
XN0258000
risk_code
36/37/38-22-39/23/24/25-23/24/25-11
hazard_code
Xi,Xn,T,F
safety_code
26-36/37-45-16-7
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 Oral

Verwendung und Herstellung

Uses · 1 Eintrag

For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.

Anwendungen · 1 Eintrag

VerwendenDuloxetine Hydrochloride acts as an antidepressant and a dual serotonin and norepinephrine reuptake inhibitor (SNRI) (1,2). Exhibits linear pharmacokinetics in mice and is not associated in any drastic changes of blood pressure or heart rate (3).

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Carbamic acid, N-methyl-N-[(3S)-3-(1-naphthalenyloxy)-3-(2-thienyl)propyl]-, ethyl ester(S)-3-(MethylaMino)-1-(2-thienyl)-1-propanolDuloxetine Related Compound F (10 mg) ((S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-3-yl)propan-1-amine hydrochloride)Duloxetine IMpurity A(±)-DuloxetineR-Duloxetine hydrochloride(S)-(+)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine(S)-N,N-Dimethyl-[3-(2-thienyl)-3-(1-naphthyloxy)propyl]amine--phosphoric acid (1:1)DULOXETINE MALEATES-(+)-N,N-Dimethyl-3-(1-naphthoxy)-3-(2-thienyl)-1-propylamine oxalate(S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine1-FluornaphthalinPhenylchlorformiat

Nachgelagerte Produkte

Duloxetine iMpurity (alpha-hydroxy)

Ergänzende Hinweise

DefinitionChEBI: A duloxetine hydrochloride in which the duloxetine moiety has S configuration.